Transient encephalopathy after paclitaxel (Taxol) infusion

Neurology

Volumn 46, Issue 6, 1996, Pages 1596-1599

  Perry, James R ^a,c   Warner, Ellen ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GADOLINIUM; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RANITIDINE; TAMOXIFEN; VINBLASTINE;

ADULT; AGED; ARTICLE; ATAXIA; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN TOXICITY; BREAST CANCER; CASE REPORT; CONFUSION; ELECTROENCEPHALOGRAPHY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUMBAR PUNCTURE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PRIORITY JOURNAL; SPEECH DISORDER;

EID: 0029948062     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1596     Document Type: Article

References (15)

1. Guchelaar HJ, Ten Napel CHH, de Vries EGE, Mulder NH. Clinical, toxicological and pharmaceutical aspects of the anti-neoplastic drug taxol: a review. Clin Oncol 1994;6:40-48.
2. Donehower RC, Rowinsky EK. An overview of experience with taxol (paclitaxel) in the U.S.A. Cancer Treat Rev 1993; 19(suppl C):63-68.
3. Warner E. Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995;5:161-169.
4. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. Monogr Natl Cancer Inst 1993;15:107-115.
5. Tuxen MK, Hanser SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191-214.
6. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273-279.
7. Capri G, Munzone E, Tarenzi E, Fultaro F, Gianni L. Optic nerve disturbance: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994;86:1099-1100.
8. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docotaxel (Taxotere). Neurology 1996;46:108-111.
9. Hilkens PHE, Verweij J, Stoter G, et al. Peripheral neuropathy induced by Docetaxel. Neurology 1996;46:104-108.
10. Apfel SC. Docetaxel neuropathy [editorial]. Neurology 1996; 46:2-3.
11. Brown T, Havlin K, Weiss G, et al. A phase 1 trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9: 1261-1267.
12. Chan ATC, Leung WT, Johnson PJ. Cerebrovascular event following taxol infusion. Clin Oncol 1994;6:202-203.
13. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine 1985;64:16-35.
14. Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (taxol). Semin Oncol 1994;20(suppl 3):16-25.
15. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4:1845-1850.